乳腺癌COX-2、P-gp的表达与新辅助化疗的关系

被引:3
作者
蔡凤林
周士福
时伟锋
吴玉玉
金琳芳
机构
[1] 苏州大学附属第四医院
关键词
乳腺癌; 新辅助化疗; COX-2; P-gp;
D O I
暂无
中图分类号
R737.9 [乳腺肿瘤];
学科分类号
摘要
目的:研究COX-2、P-gp在乳腺癌新辅助化疗前后的表达变化,及其与新辅助化疗疗效的关系。方法:应用免疫组织化学法检测48例乳腺癌新辅助化疗前后标本中COX-2、P-gp的表达。结果:新辅助化疗有效率为70.8%。化疗前后COX-2表达变化显著,由化疗前的62.5%降到化疗后的41.7%,P<0.05;P-gp表达无明显变化。化疗前后COX-2表达与P-gp正相关,P<0.05。新辅助化疗前COX-2、P-gp表达阳性者,化疗效果差,P<0.05。结论:COX-2、P-gp可作为指导乳腺癌化疗并预测化疗敏感性的分子生物学指标。
引用
收藏
页码:985 / 988
页数:4
相关论文
共 9 条
[1]  
Multidrug resistance in breastcancer:a meta-analysis of MDR1/gp170 expression and its pos-sible functional significance. Trock BJ,Leonessa F,Clarke R. Journal of the National Cancer Institute . 1997
[2]  
COX-2 overexpression inpretreatment biopsies predicts response of rectal cancers to neoadju-vant radiochemotherapy. Smith FM,Reynolds JV,Kay EW,et al. International Journal of Radiation Oncology Biology Physics . 2006
[3]  
Drug resistance in chemotherapyfor breast cancer. Saekit T,Tsuruo T,Sato W,et al. Cancer Chemother . 2005
[4]  
P-glycoprotein expression in treated and untreated human breast cancer. Schneider J,Bak M,Efferth TH et al. British Journal of Cancer . 1989
[5]  
Inhibition of cyclooxygenase(COX)-2 expression by Tet-inducible COX-2 antisense cDNAin hor-mone-refractory prostate cancer significantly slows tumor growthand improves efficacy of chemotherapeutic drugs. Dandekar DS,Lokeshwar BL. Clinical Cancer Research . 2004
[6]  
Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. Patal VA,Dunn MJ,Sorokin A. Journal of Biological Chemistry . 2002
[7]  
High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Xi H,Baldus SE,Warnecke-Eberz U, et al. Clinical Cancer Research . 2005
[8]   环氧化酶-2表达与肿瘤关系的研究进展 [J].
何仲琴 ;
李恩孝 .
现代肿瘤医学, 2005, (04) :573-575
[9]  
Drug resistance in chemotherapy for breast cancer[J] . Toshiaki Saeki,Takashi Tsuruo,Wakao Sato,Kiyoshiro Nishikawsa. &nbspCancer Chemotherapy and Pharmacology . 2005 (1)